ORIGINAL RESEARCH article
Front. Immunol.
Sec. Molecular Innate Immunity
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1635081
The Peptide Genomic Therapy Increases Antibacterial Immunity and Survival in Sepsis by Reprograming the Gene Orthologs of Human Immunodeficiencies in the Spleen and Lungs
Provisionally accepted- Vanderbilt University School of Medicine, Nashville, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Sepsis is a life-threatening complication of infections afflicting 49 million patients worldwide with 11 million sepsis-related deaths. In the USA, this growing public health problem concerns 1.7 million adult and pediatric patients. An estimated 1 million patients with asplenia or hyposplenia are particularly vulnerable to sepsis. We show that the Peptide Genomic Therapy (PGT) with the cell-penetrating Nuclear Transport Checkpoint Inhibitor (NTCI) peptide increased 29 times bacterial clearance in the spleen, a major blood-filtering immune organ in the preclinical model of sepsis, when combined with the antibiotic. Likewise, the PGT with NTCI peptide increased antibacterial immunity in the lungs, the frequent site of bacterial infections in spleen-compromised hosts. The survival reached 80% when the NTCI peptide was added to antibiotic, compared to 44% with meropenem alone. The NTCI peptide reprogrammed the expression of the gene orthologs responsible for human immunodeficiencies, also referred to as the Inborn Errors of Immunity (IEI). The 227 IEI genes were reprogrammed in the spleen and 215 in the lungs, while the mediators of inflammation in blood (IL-6, IL-10, TNFα, Interferon γ, and MCP1) were normalized by the NTCI peptide. Thus, the PGT with NTCI peptide combined with antibiotic significantly increased the antibacterial immunity in the spleen and lungs and almost doubled survival in sepsis.
Keywords: inborn errors of immunity (IEI), nuclear transport checkpoint inhibitor (NTCI), Polymicrobial sepsis, cSN50.1, Cell-Penetrating Peptides, inflammatory regulome, Gene Expression, RNAseq
Received: 25 May 2025; Accepted: 10 Oct 2025.
Copyright: © 2025 Hawiger, Qiao, Zienkiewicz and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jacek Hawiger, jack.hawiger@vanderbilt.edu
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.